Mesentericin Y105, a bacteriocin produced by a Leuconostoc mesenteroides strain, dissipates the plasma membrane potential of Listeria monocytogenes and inhibits the transport of leucine and glutamic acid. It also induces an efflux of preaccumulated amino acids from cells. In addition, the bacteriocin uncouples mitochondria by increasing state 4 respiration and decreasing state 3 respiration. The bacteriocin inhibits ATP synthase and adenine nucleotide translocase of the organelle while the affinity of ADP for its carrier is not modified. The results suggest that mesentericin Y105 acts by inducing, directly or indirectly, pore formation in the energy-transducing membranes, especially those of its natural target.
Bacteriocins are antibacterial peptides or proteins that are secreted by bacteria and act on target cells by various mechanisms, most of which are, as yet, unclear. In the group of colicins, two classes may be distinguished on the basis of their mode of action. The major class contains colicins (El, Ia, A, B, K, and N) which kill sensitive cells by forming ion channels in their cytoplasmic membranes (3) . The second class contains those colicins displaying a nuclease action (D, E2, E3, M, and V). Nisin is the best known bacteriocin produced by lactic acid bacteria. It has a wide spectrum of activity on gram-positive bacteria (12) and various Salmonella species and other gram-negative organisms (23) . The bacteriocin alters the permeability of the cytoplasmic membrane, leading to the efflux of amino acids and dissipating the membrane potential and ionic gradients (20) . Another bacteriocin, lactostrepcin 5 (Lac 5), which disrupts the integrity of the cell membrane of Lactococcus lactis cells, leads to the leakage of ions and ATP (28) . Lactococcin A, which acts preferentially on lactococci, increases the permeability of the cytoplasmic membrane of whole cells (26) , inhibits amino acid transport into sensitive cells and causes efflux of preaccumulated amino acids.
The bacteriocin mesentericin Y105 (mY105) produced by Leuconostoc mesenteroides Y105 exerts a bactericidal effect on Listeria monocytogenes E20 (6) (7) (8) . It is a low-molecularmass peptide (composed of 36 amino acids) that is highly thermostable and acidostable. Its primary structure closely resembles that of other recently discovered bacteriocins: leucocin A-UAL187 (5), pediocin PA-1 (9), and sakacin P and curvacin A (25) .
In this report, we present some biochemical details of the mode of action of bacteriocin mY105. In particular, its effect on L. monocytogenes E20 membrane potential was determined by using the fluorescent probe rhodamine 123 (Rh 123) and flow cytometry. Amino acid transport into Listena monocytogenes has also been investigated, in addition to an analysis of the effects of the bacteriocin on various functions of isolated mammalian mitochondria.
Action of the bacteriocin mY105 on the membrane potential Action of mY105 on amino acid transport by L. monocytogenes E20. To further investigate the last conclusion, mY105 action on amino acid transport was assessed according to the method of van Belkum et al. (26) . The study was carried out with whole cells in the presence of 0.4% (wt/vol) glucose. We started by measuring the transport of leucine, which, as has been demonstrated with lactococci (14) and is presumably true for Listeria spp., appears to be taken up by a symport with one proton and driven by the proton motive force. In the absence of mY105, the initial velocity of leucine transport is close to 0.35 pmol/min (Fig. 1) . When bacteria are preincubated with 100 AU of mY105 per ml, leucine uptake is strongly inhibited and the initial velocity of amino acid incorporation is drastically reduced (Fig. 1) . Moreover, the addition of the bacteriocin (100 AU/ml) to bacteria which had previously accumulated 9.5 pmol of leucine provokes an efflux of the amino acid. The release is very fast and involves more than 80% of the amino acid content. This would suggest that the release of leucine is mediated not by a carrier but probably by a simple leakage through the membrane. To confirm this result, glutamic acid was chosen for similar transport experiments, since its uptake, at least by streptococci, is unidirectional and is not driven by the proton motive force (18) . As expected, an efflux of glutamic acid is also observed when 100 AU of mY105 per ml was added to cells which had first incorporated 3.3 pmol of the amino acid (data not shown). As with leucine, mY105 does not induce a total efflux of preincorporated glutamic acid. Nevertheless, 65% of the glutamic acid was rapidly released into the incubation medium. This would suggest that a small fraction of the amino acids transported into the cells is incorporated into proteins during the incubation time (nearly 1 h).
Similar transport inhibitions have also been observed with alanine amino-isobutyric acid (a nonmetabolizable analog of alanine) and lysine (data not shown). Since mY105 affects the transport of all the amino acids tested similarly, it is suggested that the bacteriocin could modify the structure of the target membrane. The nonaccumulation and then the efflux of amino acids from sensitive cells agree well with the data presented above indicating that mY105 dissipates the membrane potential of target bacteria. Both types of results could be explained by membrane permeabilization. Thus, the earliest events of mY105 action may be the formation of pores in the plasma membrane followed by the depolarization and the efflux of low-molecular-mass cytoplasmic compounds.
The bacteriocin has been also assessed in leucine transport by L. mesenteroides Y105 and its mutant L. mesenteroides Y30 (Table 2) . It slightly affects the transport by the strain Y105 (Bac+) while its effect is more pronounced on the mutant Y30 (Bac-) which does not produce bacteriocin L. monocytogenes E20 cells are, nevertheless, the most sensitive to mY105 action ( Table 2) .
Action of the bacteriocin on rat liver mitochondria respiration. Isolated rat liver mitochondria were prepared by differential centrifugation (10 (Fig. 2) . For the two respiration states, modifications of oxygen consumption by mitochondria, upon addition of bacteriocin, were immediately observed. Similar results were obtained by using rat liver mitochondria oxidizing glutamate instead of succinate (data not shown). The inhibition of ADP-stimulated respiration by bacteriocin was due to the uncoupling of mitochondria.
Inhibition of mitochondrial ATP synthesis and adenine nucleotide translocase. In order to determine more precisely how the bacteriocin inhibits ADP-stimulated respiration, the effects of mY105 on ATP synthesis by intact mitochondria were assessed by a colorimetric assay (24) (Fig. 3) . The bacteriocin strongly decreases ATP production in wellcoupled rat liver mitochondria. At a concentration of 25.6 AU of bacteriocin per ml, ATP synthesis is completely inhibited, a result which is in good agreement with the above-reported results indicating a decrease of state 3 respiration following bacteriocin addition. This inhibition may be explained by the dissipation of the membrane potential, a component of the proton motive force needed for ATP synthesis.
The ADP-ATP translocase has been quantified in beef heart mitochondria (22) by using radiolabeled atractyloside, a specific inhibitor of the adenine nucleotide translocase which interacts with regions exposed on the cytoplasmic side of the inner membrane (27) . While ATP synthesis has been found to be completely inhibited at 25.6 AU of mY105 per ml (Fig. 3) , the association of ADP to its translocator, estimated by the amount of [3H]atractyloside bound to mitochondria, decreases by only 18% (data not shown). Since atractyloside is a competitive inhibitor of ADP, it may be suggested that bacteriocin, at relatively low concentrations, does not strongly prevent the binding of ADP to its carrier. Consequently, ATP synthesis inhibition cannot be entirely explained by the modification of the ADP binding to the protein. However, adenine nucleotide translocase activity measured by the rate of ADP translocated across inner mitochondria membrane appears to be more sensitive to the bacteriocin. With increasing bacteriocin concentrations (5.1 to 76.8 AU/ml), the rate of ADP transport declines (Fig. 4) . At mY105 concentrations higher than 25.6 AU/ml, ADP transport is almost completely inhibited, since the same kinetics are obtained in the presence of 20 p.M carboxyatractyloside, a known inhibitor of ADP transport. Hence, the adenine nucleotide translocase activity is affected more than the affinity of ADP to its carrier. Consequently, the action of mY105 on ADP transport could be another inhibiting factor of ATP synthesis.
Apparently, mY105 action on L. monocytogenes E20 could be due to its ability to produce pore formation in target membranes. Its mode of action may be similar to that of other small pore-forming peptide antibiotics (2, 4, 16, 21) . For some bacteria (11), a membrane-associated protein that acts as a receptor for bacteriocins has been described. Such 120 I T . (27) . The kinetics of ADP transport were recorded in the absence or presence of various concentrations of mY105. A 5-min preincubation with mYlO5 was done before starting of the transport. The translocase activity was then measured 30 s following the beginning of the reaction. NOTES 3235 a mechanism has also been shown for channel-forming colicins which first bind to specific receptors located at the surface of susceptible cells (15 (1) .
From the known size of mY105 (36 amino acids), it appears that such pores cannot be formed by only one molecule; it must rather be assumed that peptide molecules aggregate or act in conjunction with other membrane molecules to establish a functional pore, as has been previously described for most pore-forming peptides (17) .
